Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT01343277
Registration number
NCT01343277
Ethics application status
Date submitted
26/04/2011
Date registered
28/04/2011
Date last updated
26/08/2016
Titles & IDs
Public title
A Study of Trabectedin or Dacarbazine for the Treatment of Patients With Advanced Liposarcoma or Leiomyosarcoma
Query!
Scientific title
A Randomized Controlled Study of YONDELIS (Trabectedin) or Dacarbazine for the Treatment of Advanced Liposarcoma or Leiomyosarcoma
Query!
Secondary ID [1]
0
0
ET743SAR3007
Query!
Secondary ID [2]
0
0
CR018004
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Advanced Liposarcoma or Leiomyosarcoma
0
0
Query!
Condition category
Condition code
Cancer
0
0
0
0
Query!
Sarcoma (also see 'Bone') - soft tissue
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Trabectedin
Treatment: Drugs - Dacarbazine
Experimental: Trabectedin -
Active Comparator: Dacarbazine -
Treatment: Drugs: Trabectedin
Type=exactly number, unit=mg/m2, number=1.5, form=intravenous infusion, route=intravenous use. Once every 3 weeks until disease progression or signs of toxicity.
Treatment: Drugs: Dacarbazine
Type=exactly number, unit=g/m2, number=1, form=intravenous infusion, route=intravenous use. Once every 3 weeks until disease progression or signs of toxicity.
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Overall Survival (OS)
Query!
Assessment method [1]
0
0
The OS is defined as the time from the date of first dose of study drug to date of death from any cause. If the participant is alive or the vital status is unknown, the participant will be censored at the date the participant will be last known to be alive.
Query!
Timepoint [1]
0
0
approximately 3 years 8 months (From Study start date [27 May 2011] up to final analysis data cut-off [05 January 2015]
Query!
Secondary outcome [1]
0
0
Progression-Free Survival (PFS)
Query!
Assessment method [1]
0
0
The Progression-Free Survival (PFS) was assessed as median number of months from baseline until the first documented sign of disease progression (increase in disease; radiographic, clinical, or both) or death due to any cause, whichever occurred earlier. Independent Data Monitoring Committee performed ongoing safety monitoring and conducted the interim analysis after 189 death events and 329 PFS events were observed.
Query!
Timepoint [1]
0
0
approximately 2 years 4 months (From Study start date [27 May 2011] up to interim analysis data cut-off [16 September 2013])
Query!
Secondary outcome [2]
0
0
Time to Progression
Query!
Assessment method [2]
0
0
Time interval in months between the date of randomization and the date of disease progression or death due to progression, whichever occurred first.
Independent Data Monitoring Committee performed ongoing safety monitoring and conducted the interim analysis after 189 death events and 329 PFS events were observed.
Query!
Timepoint [2]
0
0
approximately 2 years 4 months (From Study start date [27 May 2011] up to interim analysis data cut-off [16 September 2013])
Query!
Secondary outcome [3]
0
0
Objective Response Rate
Query!
Assessment method [3]
0
0
The objective response rate (ORR) is defined as the percentage of participants who achieved a Complete response (CR) or partial response (PR) as best responses. according to Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST). CR defined as disappearance of all target lesions. Any pathological lymph nodes must have reduction in short axis to less than 10 millimeter (mm). PR defined as at least 30 percent (%) decrease in sum of the diameters of the target lesions taking as reference the Baseline sum diameters. Confirmed responses are those that persist on repeat imaging study for at least 4 weeks after initial documentation of response. Independent Data Monitoring Committee performed ongoing safety monitoring and conducted the interim analysis after 189 death events and 329 PFS events were observed.
Query!
Timepoint [3]
0
0
approximately 2 years 4 months (From Study start date [27 May 2011] up to interim analysis data cut-off [16 September 2013])
Query!
Secondary outcome [4]
0
0
Duration of Response
Query!
Assessment method [4]
0
0
Duration of response is defined as the time from the date of initial documentation of a response (CR or PR) to the date of first documented evidence of progressive disease (or relapse for participants who experience CR during the study) or death.
Independent Data Monitoring Committee performed ongoing safety monitoring and conducted the interim analysis after 189 death events and 329 PFS events were observed.
Query!
Timepoint [4]
0
0
approximately 2 years 4 months (From Study start date [27 May 2011] up to interim analysis data cut-off [16 September 2013])
Query!
Secondary outcome [5]
0
0
Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
Query!
Assessment method [5]
0
0
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.
Query!
Timepoint [5]
0
0
approximately 3 years 8 months (From Study start date [27 May 2011] up to final analysis data cut-off [05 January 2015])
Query!
Eligibility
Key inclusion criteria
- Histologically proven, unresectable, locally advanced or metastatic liposarcoma
(dedifferentiated, myxoid round cell, or pleomorphic) or leiomyosarcoma. Participants
must have a pathology report indicating the diagnosis of liposarcoma or leiomyosarcoma
that has been reviewed by the sponsor before randomization may occur
- Treated in any order with at least: an anthracycline and ifosfamide containing
regimen, or an anthracycline containing regimen and 1 additional cytotoxic
chemotherapy regimen
- Measurable disease at baseline in accordance with RECIST Version 1.1
- Pathology specimens (example [e.g.], tumor blocks or unstained slides) for potential
centralized pathology review and biomarker studies
- ECOG Performance Status score of 0 or 1
- Adequate recovery from prior therapy, all side effects (except alopecia) have resolved
to Grade 1 or less according to the National Cancer Institute - Common Terminology
Criteria of Adverse Events (NCI-CTCAE) Version 4.0
- Adequate organ function as evidenced by the following peripheral blood counts or serum
chemistry values: hemoglobin 9 gram per deciliters (g/dL), absolute neutrophil count
(ANC) 1,500/L, platelet count 100,000/L, serum creatinine 1.5*the upper limit of
normal (ULN), creatine phosphokinase (CPK) 2.5 Upper Limit of Normal [ULN]
- Adequate hepatic function as evidenced by the following serum chemistry values: total
bilirubin, ULN. If total bilirubin is greater than (>) ULN, measure indirect bilirubin
to evaluate for Gilbert's syndrome (if direct bilirubin is within normal range,
participant may be eligible) ALP 2.5 x ULN; Trabectedin: if the ALP is >2.5 x ULN,
then an ALP liver fraction or 5-nucleotidase must be obtained and ULN, AST and ALT 2.5
ULN
- Negative pregnancy test (urinary or serum beta-HCG) at screening (applicable to women
of child bearing potential who are sexually active)
- Female participants must be postmenopausal (no spontaneous menses for at least 2
years), surgically sterile (have had a hysterectomy or bilateral oophorectomy, tubal
ligation, or otherwise be incapable of pregnancy), abstinent (at the discretion of the
investigator), or if sexually active, be practicing an effective method of birth
control. Male participants must agree to use an adequate contraception method as
deemed appropriate by the investigator (e.g., vasectomy, double-barrier, partner using
effective contraception) and to not donate sperm for a minimum of 5 months after
treatment discontinuation
Optional Extension Phase (OEP) Phase:
- Documentation for inclusion criteria histologically proven, unresectable, locally
advanced or metastatic liposarcoma (dedifferentiated, myxoid round cell, or
pleomorphic) or leiomyosarcoma. Participants must have a pathology report indicating
the diagnosis of liposarcoma or leiomyosarcoma that has been reviewed by the sponsor
before randomization may occur and treated in any order with at least: an
anthracycline and ifosfamide containing regimen, or an anthracycline containing
regimen and 1 additional cytotoxic chemotherapy regimen do not need to be reviewed by
the Sponsor
- Collection of the specimen: Pathology specimens (example (e.g.), tumor blocks or
unstained slides) for potential centralized pathology review and biomarker studies is
not applicable
- Documentation of inclusion criteria adequate organ function as evidenced by the
following peripheral blood counts or serum chemistry values: hemoglobin 9 gram per
deciliters (g/dL), absolute neutrophil count (ANC) 1,500/L, platelet count 100,000/L,
serum creatinine 1.5*the upper limit of normal (ULN), creatine phosphokinase (CPK)
2.5*ULN and adequate hepatic function as evidenced by the following serum chemistry
values: total bilirubin, ULN. If total bilirubin is greater than (>) ULN, measure
indirect bilirubin to evaluate for Gilbert's syndrome (if direct bilirubin is within
normal range, participant may be eligible) ALP <= 2.5*ULN; Trabectedin: if the ALP is
>2.5*ULN, then an ALP liver fraction or 5-nucleotidase must be obtained and ULN, AST
and ALT 2.5 ULN will be reviewed by the Sponsor before enrollment in the OEP may occur
Query!
Minimum age
15
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
- Potential participants who meet any of the following criteria will be excluded from
participating in the study: Prior exposure to trabectedin or dacarabazine, less than 3
weeks from last dose of systemic cytotoxic therapy, radiation therapy, or therapy with
any investigational agent, other malignancy within past 3 years. Exceptions: basal or
nonmetastatic squamous cell carcinoma of the skin, cervical carcinoma in situ, or
Federation Internationale de Gynecologie et d'Obstetrique (FIGO) Stage 1 carcinoma of
the cervix
- Known central nervous system metastasis
- Known significant chronic liver disease, such as cirrhosis or active hepatitis
(potential participants who test positive for hepatitis B surface antigen or hepatitis
C antibodies are allowed provided they do not have active disease requiring antiviral
therapy)
- Myocardial infarct within 6 months before enrollment, New York Heart Association Class
II or greater heart failure, uncontrolled angina, severe uncontrolled ventricular
arrhythmias, clinically significant pericardial disease, or electrocardiographic
evidence of acute ischemic or active conduction system abnormalities
- Uncontrolled intercurrent illness including, but not limited to, poorly controlled
hypertension or diabetes, ongoing active infection, or psychiatric illness/social
situation that may potentially impair the participant's compliance with study
procedures
- Unwilling or unable to have a central venous catheter
- Known allergies, hypersensitivity, or intolerance to trabectedin, dacarbazine,
dexamethasone, or their excipients
- Pregnant or breast-feeding
- Any condition that, in the opinion of the investigator, would compromise the
well-being of the participant or the study or prevent the participant from meeting or
performing study requirements
OEP phase:
- Potential participants who meet any of the following criteria will be excluded from
Participating in the study: Prior exposure to trabectedin, less than 3 weeks from last
dose of systemic cytotoxic therapy, radiation therapy, or therapy with any
investigational agent, other malignancy within past 3 years. Exceptions: basal or
nonmetastatic squamous cell carcinoma of the skin, cervical carcinoma in situ, or
Federation Internationale de Gynecologie et d'Obstetrique (FIGO) Stage 1 carcinoma of
the cervix does not apply
- Treated in any order with at least: an anthracycline and ifosfamide containing
regimen, or an anthracycline containing regimen and 1 additional cytotoxic
chemotherapy regimen with less than 3 weeks from last dose of systemic anticancer
therapy, radiation therapy, or therapy with any investigational agent
- Known allergies, hypersensitivity, or intolerance to dacarbazine does not apply
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
1/06/2011
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
1/04/2016
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
579
Query!
Recruitment in Australia
Recruitment state(s)
Query!
Recruitment hospital [1]
0
0
- Malvern
Query!
Recruitment hospital [2]
0
0
- Randwick
Query!
Recruitment hospital [3]
0
0
- Subiaco
Query!
Recruitment hospital [4]
0
0
- Woolloongabba
Query!
Recruitment postcode(s) [1]
0
0
- Malvern
Query!
Recruitment postcode(s) [2]
0
0
- Randwick
Query!
Recruitment postcode(s) [3]
0
0
- Subiaco
Query!
Recruitment postcode(s) [4]
0
0
- Woolloongabba
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Arizona
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Arkansas
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
California
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Colorado
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Connecticut
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Florida
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Georgia
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Idaho
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Illinois
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Indiana
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
Iowa
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
Kansas
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
Kentucky
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
Louisiana
Query!
Country [15]
0
0
United States of America
Query!
State/province [15]
0
0
Maryland
Query!
Country [16]
0
0
United States of America
Query!
State/province [16]
0
0
Massachusetts
Query!
Country [17]
0
0
United States of America
Query!
State/province [17]
0
0
Michigan
Query!
Country [18]
0
0
United States of America
Query!
State/province [18]
0
0
Mississippi
Query!
Country [19]
0
0
United States of America
Query!
State/province [19]
0
0
Missouri
Query!
Country [20]
0
0
United States of America
Query!
State/province [20]
0
0
Nebraska
Query!
Country [21]
0
0
United States of America
Query!
State/province [21]
0
0
Nevada
Query!
Country [22]
0
0
United States of America
Query!
State/province [22]
0
0
New Hampshire
Query!
Country [23]
0
0
United States of America
Query!
State/province [23]
0
0
New Jersey
Query!
Country [24]
0
0
United States of America
Query!
State/province [24]
0
0
New Mexico
Query!
Country [25]
0
0
United States of America
Query!
State/province [25]
0
0
New York
Query!
Country [26]
0
0
United States of America
Query!
State/province [26]
0
0
North Carolina
Query!
Country [27]
0
0
United States of America
Query!
State/province [27]
0
0
Ohio
Query!
Country [28]
0
0
United States of America
Query!
State/province [28]
0
0
Oklahoma
Query!
Country [29]
0
0
United States of America
Query!
State/province [29]
0
0
Oregon
Query!
Country [30]
0
0
United States of America
Query!
State/province [30]
0
0
Pennsylvania
Query!
Country [31]
0
0
United States of America
Query!
State/province [31]
0
0
South Carolina
Query!
Country [32]
0
0
United States of America
Query!
State/province [32]
0
0
Tennessee
Query!
Country [33]
0
0
United States of America
Query!
State/province [33]
0
0
Texas
Query!
Country [34]
0
0
United States of America
Query!
State/province [34]
0
0
Utah
Query!
Country [35]
0
0
United States of America
Query!
State/province [35]
0
0
Virginia
Query!
Country [36]
0
0
United States of America
Query!
State/province [36]
0
0
Washington
Query!
Country [37]
0
0
United States of America
Query!
State/province [37]
0
0
West Virginia
Query!
Country [38]
0
0
United States of America
Query!
State/province [38]
0
0
Wisconsin
Query!
Country [39]
0
0
Brazil
Query!
State/province [39]
0
0
Bahia
Query!
Country [40]
0
0
Brazil
Query!
State/province [40]
0
0
Barretos
Query!
Country [41]
0
0
Brazil
Query!
State/province [41]
0
0
Ijuí
Query!
Country [42]
0
0
Brazil
Query!
State/province [42]
0
0
Porto Alegre
Query!
Country [43]
0
0
Brazil
Query!
State/province [43]
0
0
Sao Paulo
Query!
Country [44]
0
0
Brazil
Query!
State/province [44]
0
0
São Paulo
Query!
Country [45]
0
0
New Zealand
Query!
State/province [45]
0
0
Auckland
Query!
Country [46]
0
0
New Zealand
Query!
State/province [46]
0
0
Wellington
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
Janssen Research & Development, LLC
Query!
Address
Query!
Country
Query!
Other collaborator category [1]
0
0
Commercial sector/Industry
Query!
Name [1]
0
0
PharmaMar
Query!
Address [1]
0
0
Query!
Country [1]
0
0
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
The purpose of this study is to evaluate whether overall survival for the trabectedin group
is superior to the dacarbazine group for patients with advanced L-sarcoma (liposarcoma or
leiomyosarcoma).
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT01343277
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Janssen Research & Development, LLC Clinical Trial
Query!
Address
0
0
Janssen Research & Development, LLC
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT01343277
Download to PDF